肝转移为主的转移性结直肠癌的肝内治疗
Intrahepatic therapy for liver-dominant metastatic colorectal cancer.
作者信息
De Groote Kerlijne, Prenen Hans
机构信息
Kerlijne De Groote, Hans Prenen, Department of Gastroenterology, University Hospitals Leuven, B-3000 Leuven, Belgium.
出版信息
World J Gastrointest Oncol. 2015 Sep 15;7(9):148-52. doi: 10.4251/wjgo.v7.i9.148.
Abstract
In patients with metastatic colorectal cancer, the liver is the most common site of metastatic disease. In patients with liver-dominant disease, consideration needs to be given to locoregional treatments such as hepatic arterial infusion chemotherapy, transarterial chemoembolisation and selective internal radiation therapy because hepatic metastases are a major cause of liver failure especially in chemorefractory disease. In this review we provide insights on the published literature for locoregional treatment of liver metastases in metastatic colorectal cancer.
摘要
在转移性结直肠癌患者中，肝脏是最常见的转移部位。对于以肝脏转移为主的患者，需要考虑局部区域治疗，如肝动脉灌注化疗、经动脉化疗栓塞和选择性内放射治疗，因为肝转移是肝衰竭的主要原因，尤其是在化疗难治性疾病中。在本综述中，我们对已发表的关于转移性结直肠癌肝转移局部区域治疗的文献进行了深入分析。
相似文献
1
Intrahepatic therapy for liver-dominant metastatic colorectal cancer.
World J Gastrointest Oncol. 2015 Sep 15;7(9):148-52. doi: 10.4251/wjgo.v7.i9.148.
2
Liver-directed therapy in metastatic colorectal cancer.
Expert Rev Anticancer Ther. 2017 Aug;17(8):745-758. doi: 10.1080/14737140.2017.1345629. Epub 2017 Jun 28.
3
Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases.
Cochrane Database Syst Rev. 2013 Apr 30(4):CD009498. doi: 10.1002/14651858.CD009498.pub3.
4
Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review.
J Surg Oncol. 2014 Aug;110(2):182-96. doi: 10.1002/jso.23619. Epub 2014 Apr 24.
5
Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer.
Hepat Oncol. 2014 Apr;1(2):215-228. doi: 10.2217/hep.13.21. Epub 2014 Mar 20.
6
Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver.
Semin Oncol. 2010 Apr;37(2):149-59. doi: 10.1053/j.seminoncol.2010.03.005.
7
Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis.
Surg Oncol Clin N Am. 2015 Jan;24(1):149-66. doi: 10.1016/j.soc.2014.09.004. Epub 2014 Oct 7.
8
The role of image-guided therapy in the management of colorectal cancer metastatic disease.
Eur J Cancer. 2017 Apr;75:231-242. doi: 10.1016/j.ejca.2017.01.010. Epub 2017 Feb 24.
9
Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases.
Cochrane Database Syst Rev. 2012 Sep 12(9):CD009498. doi: 10.1002/14651858.CD009498.pub2.
10
Transarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know.
Eur J Radiol Open. 2020 May 13;7:100236. doi: 10.1016/j.ejro.2020.100236. eCollection 2020.
引用本文的文献
1
Shared liver-like transcriptional characteristics in liver metastases and corresponding primary colorectal tumors.
J Cancer. 2018 Apr 6;9(8):1500-1505. doi: 10.7150/jca.23017. eCollection 2018.
2
Comparison of overall survival in patients with unresectable hepatic metastases with or without transarterial chemoembolization: A Propensity Score Matching Study.
Sci Rep. 2016 Oct 13;6:35336. doi: 10.1038/srep35336.
3
SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation.
Mol Oncol. 2016 Aug;10(7):1133-45. doi: 10.1016/j.molonc.2016.05.003. Epub 2016 May 21.
本文引用的文献
1
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.
2
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Ann Surg. 2015 Feb;261(2):353-60. doi: 10.1097/SLA.0000000000000614.
3
A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.
J Cancer Res Clin Oncol. 2014 Apr;140(4):537-47. doi: 10.1007/s00432-013-1564-4. Epub 2013 Dec 7.
4
Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period.
Int J Cancer. 2014 Mar 1;134(5):1225-31. doi: 10.1002/ijc.28443. Epub 2013 Sep 3.
5
Oncological management of unresectable liver metastases.
Dig Dis. 2012;30 Suppl 2:137-42. doi: 10.1159/000342047. Epub 2012 Nov 23.
6
7
Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review.
Hepatogastroenterology. 2012 Jan-Feb;59(113):255-60. doi: 10.5754/hge10240.
8
9
Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol.
Cancer. 2011 Jan 15;117(2):343-52. doi: 10.1002/cncr.25387. Epub 2010 Sep 9.
10
Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.
Ann Surg Oncol. 2011 Jan;18(1):192-8. doi: 10.1245/s10434-010-1288-5. Epub 2010 Aug 26.
Zotero 插件